Latest news & insights

Boyds is pleased to announce the appointment of regulatory operations and publishing professional Michelle Hackney to lead our new in-house Regulatory Operations offering.

Boyds are excited to announce the expansion of its service offering with the launch of a new in-house regulatory operations service that will enable the company to support the full lifecycle of its clients’ drug development projects.

We are delighted to congratulate Chief Medical Officer at Boyds, Dr Karen Mullen, on being recognised as a Global Fellow in Medicines Development (GFMD) by the Academy of Global Medicines Development Professionals.

Boyds is delighted to announce the appointment of regulatory affairs professional Eric Hardter to our US team.

We are excited to announce our involvement in the upcoming #AgileLeaders Forum on Successful Development of C&G Therapies, with special guest speaker, Professor Alan Boyd.

The Cat, local radio station for Crewe and Nantwich, has announced a partnership with Boyds, global drug development consultancy.

If you are running any clinical trials, approved under the Clinical Trials Directive, that will continue to run after 31 January 2025, you will need to comply with the Clinical Trials Regulation (Regulation (EU) No 536/2014)

Our leading Regulatory Affairs Group has promoted Dr Sabine Rühle to Director of Regulatory Affairs and Navila Rehman to Senior Manager, Quality Assurance and Regulatory Operations.